SLC12A2 Gene Curation
Gene-disease assertions not curated here (add link or write note): did not curate the AD hearing loss phenotype, but note that these variants cluster to exon 21, and Exon 21 containing isoform the only transcript in the developing cochlea (McNeill et al., 2020).
TABLE 1 IN 33500540 HAS A GOOD SUMMARY OF CASES
Disease | Kilquist syndrome |
---|---|
Inheritance | Autosomal recessive |
Prevalence |
Source: |
Rapid or full curation? | Rapid Full |
No ClinGen Curations, 3 strong curations from Invitae (AD hearing loss, AD Delpire-McNeill syndrome, AR Kilquist syndrome)
| |
Clinical Validity Scoring Notes and points |
AR Kilquist syndrome
Experimental
Source: |
Clinical Validity Points Total | >12 Source: |
Clinical Validity Classification Definitive (12pts) Strong (12pts) Moderate (7-11pts) Limited (0.1-6pts) No genetic evidence Refuted Disputed | Definitive (replicated 2019-2021) Source:
|
Molecular Mechanism Loss of function Gain of function Dominant negative Unknown Other | Loss of function See clinical validity scoring, all LOF PMID: 34797034, 32754646, 30740830, 33500540 |
Penetrance Complete (100%) High (≥80%) Moderate (<80% and >20%) Low (≤20%) (list source/PMID) |
|
Age of Onset Congenital Pediatric Adolescent Adulthood Late adulthood (list source/PMID) | Congenital |
Severity |
|
Clinical Features |
Sources:
|
HPO Terms |
|
Gene SOPs & Notes |
|
Curation Summary |
|
Case ID, Curator name, Date, Jira ticket link | Andrea Oza E3800892000, 09.23.24 |
Disease | Delpire-McNeill syndrome |
---|---|
Inheritance | Autosomal dominant |
Prevalence |
Source: |
Rapid or full curation? | Rapid - determine if LOF is mechanism Full |
No ClinGen Curations, 3 strong curations from Invitae (AD hearing loss, AD Delpire-McNeill syndrome, AR Kilquist syndrome)
| |
Clinical Validity Scoring Notes and points |
PMID: 32658972 - cohort study
c.3076_3086del11 p.(Val1026Phefs*2) - PMID: 37399495 / 27900370 - It looks like these paper report the same individual but nomenclature is incorrect in PMID: 37399495, reporting patient from UDN program with 5:127514355, ATGTCTGGTGGC > A leading to p.V1226Ffs2. obstructive apnea, vomiting, dehydration, decreased energy and fatigue, exercise intolerance, left ventricular dilated myopathy, and seizure-like symptoms. Variant was coinjected into Xenopus oocytes, showed totoal absence of function, no evidence of dominant negative effect. We demonstrated that the wild-type NKCC1 transporter trafficked properly to the basolateral membrane as expected, but surprisingly, the mutant transporter mis-trafficked to the apical membrane. More intriguing was the discovery that the mutant transporter could, likely through dimerization, send some wild-type transporters to the apical membrane (16). Thus, this mistargeting constitutes a significant dominant negative effect in epithelial cells. Further research revealed that the mis-trafficking was due to the loss of a di-leucine-like motif at the extreme end of the protein. Supports dominant negative effect? PMID:
Experimental
Source: |
Clinical Validity Points Total |
Source: |
Clinical Validity Classification |
Source: |
Molecular Mechanism | Unknown - possibly dominant negative
Notes:
|
Penetrance (list source/PMID) |
Source: |
Age of Onset (list source/PMID) |
|
Severity |
|
Clinical Features |
Sources: |
HPO Terms |
|
Gene SOPs & Notes | LINK if SOP is a long document. Short notes if it is easy to digest. eg. Last known truncating variant |
Curation Summary |
|
Case ID, Curator name, Date, Jira ticket link | Andrea Oza E3800892000, 09.23.24 |